London, UK – 12 March 2026 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform and Etcembly Ltd, a techbio company leveraging generative AI for the development of…
Avigen Selected to Participate in the DeepTech Catalyst Biotech Incubator Programme
Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation London, UK – 11 February 2026 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced its…
Avigen Strengthens Growth Trajectory Through Royal Academy of Engineering Enterprise Fellowship Award
London, UK – 1 January 2026 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced that Neelima KC, Founder of Avigen Ltd. has been awarded a…
Avigen enters Collaboration with NK:IO to Advance NK Cell Therapies for Solid Tumours
London, UK – 12 September 2025 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced a preclinical research and development (R&D) collaboration with NK:IO, a biotechnology…
Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation
Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation London, UK – 1 April 2025 – Avigen (“the Company”), a privately held Contract Research Organisation spun out from Imperial College London developing advanced preclinical immunotherapy R&D services using its proprietary…
Avigen Raises £300k from SFC Capital to Launch CRO Services
Avigen Raises £300k from SFC Capital to Launch Immunotherapy CRO Services London, UK – 31 March 2025 – Avigen (“the Company”), a privately held Contract Research Organisation spun out from Imperial College London developing advanced preclinical immunotherapy R&D services using its…